New biologic MK-1045 targets Hard-to-Treat blood cancers
NCT ID NCT07709000
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This phase 2 trial tests an experimental biologic called MK-1045 in people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study aims to see if MK-1045 is safe and tolerable, and how many participants respond to treatment. Participants receive MK-1045 by intravenous infusion, along with premedications to reduce side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a biologic called MK-1045 (also known as CN201)
- What this could lead to
- If successful, MK-1045 could offer a new treatment option for people with hard-to-treat CLL or SLL.
- What could go wrong
- This is an early-phase trial with only 60 participants, so results may not apply broadly. Side effects and lack of response are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
- Could a common arthritis drug shield transplant patients from a dangerous virus?
- New transplant recipe aims to tame Graft-Versus-Host disease
- Can a tailored exercise and diet plan beat cancer fatigue?
- Shorter chemo before transplant may cut severe side effects for blood cancer patients
- New combo aims to put CLL into deep remission and let patients stop treatment